Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

The following is a summary of "Impact of sodium-glucose cotransporter‐2 inhibitors in patients with recent versus previous ...

Researchers have identified in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT2i) could diminish the risk ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...